Cytogenetic features
. | All . | Aged younger than 35 years . | Aged 35 years or older . | P . |
|---|---|---|---|---|
| Patients, no. | 110 | 51 | 59 | — |
| inv(16)/t(16;16), no. | 109/1 | 51/0 | 58/1 | — |
| AN/AA status,* no. | 45/64 | 26/25 | 19/39 | .08 |
| Associated abnormalities, no. | 34 | 11 | 23 | .06 |
| Number abnormalities only, no. | 18 | 7 | 11 | .33† |
| Including +8 | 9 | 2 | 7 | — |
| Including +22 | 9 | 3 | 6 | — |
| Including +21 | 3 | 3 | 0 | — |
| Including structure abnormalities, no. | 16 | 4 | 12 | .05† |
| del(7q) | 4 | 1 | 3 | — |
| del(16q) | 3 | 1 | 2 | — |
| Other | 9 | 2 | 7 | — |
. | All . | Aged younger than 35 years . | Aged 35 years or older . | P . |
|---|---|---|---|---|
| Patients, no. | 110 | 51 | 59 | — |
| inv(16)/t(16;16), no. | 109/1 | 51/0 | 58/1 | — |
| AN/AA status,* no. | 45/64 | 26/25 | 19/39 | .08 |
| Associated abnormalities, no. | 34 | 11 | 23 | .06 |
| Number abnormalities only, no. | 18 | 7 | 11 | .33† |
| Including +8 | 9 | 2 | 7 | — |
| Including +22 | 9 | 3 | 6 | — |
| Including +21 | 3 | 3 | 0 | — |
| Including structure abnormalities, no. | 16 | 4 | 12 | .05† |
| del(7q) | 4 | 1 | 3 | — |
| del(16q) | 3 | 1 | 2 | — |
| Other | 9 | 2 | 7 | — |